查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403494

2030 年肺動脈高血壓市場預測：按產品、類型、給藥途徑、最終用戶和地區進行的全球分析

Pulmonary Arterial Hypertension Market Forecasts to 2030 - Global Analysis By Type, Product, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肺動脈高血壓市場規模為 54 億美元，預計預測期內複合年成長率為 7.4%，到 2030 年將達到 89 億美元。

肺動脈高血壓是一種罕見且危險的疾病，其特徵是向肺部供血的動脈血壓升高。呼吸困難和心臟衰竭是肺動脈壓力升高引起的一些併發症。市面上有多種治療方法旨在控制和緩解 PAH 症狀，最終目標是改善患者的整體健康狀況和前景。

根據《美國管理醫療雜誌》報道，PAH 是一種罕見疾病，在美國和歐洲每百萬人中有 15 至 50 人受到影響。 52.6% 的 PAH 病例是特發性、遺傳性和厭食症所致。 PAH 通常發生在 30 歲至 60 歲之間的女性。

危險因子增加

PAH 通常與結締組織疾病、先天性心臟疾病和肝病等潛在疾病有關。隨著這些危險因子的發生率在全球範圍內增加，PAH 的盛行率也在增加。此外，久坐的生活方式和接觸環境毒素等生活方式因素也會導致多環芳烴患者的增加。人口高齡化進一步增加了風險，因為 PAH 更常見於老年人。這些風險因素的負擔日益加重，導致受 PAH 影響的人數迅速增加，推動了對創新治療方法、藥物介入和醫學進步的需求。

與治療選擇相關的高成本

現有治療方案的高成本是肺動脈高血壓市場的主要障礙。 PAH 治療（包括磷酸二酯酶 5 抑制劑、內皮素受體拮抗和細胞週期蛋白類似物）的費用對於患者和醫療保健系統來說都是高昂的。 PAH 的診斷和治療很複雜，需要專門的醫療基礎設施和知識。這些經濟和實際限制使得提供有效的多環芳烴治療變得困難，並突出需要更容易獲得和價格合理的治療選擇。

開發創新治療方法

肺動脈高血壓市場提供了許多機會，包括開發新型治療策略和針對性藥物。技術和科學的發展使得找到針對 PAH 根本原因的新的、更有效的治療方法成為可能。改善早期診斷和提高意識將使我們能夠收治更多患者。

治療選擇有限

肺動脈高血壓市場因治療選擇匱乏和難以創造有效的治療方法而受到嚴重威脅。由於 PAH 是一種嚴重的疾病，由於疾病複雜的病理以及對新作用機制的需求，新治療藥物的開發具有挑戰性。然而，缺乏多樣化和有針對性的治療方法可能會限制患者的選擇並阻礙整個 PAH 市場的擴張。

COVID-19 的影響：

COVID-19 的疫情對市場產生了重大影響。封鎖期間，肺動脈高壓患者難以獲得醫療照護和治療。由於醫療保健系統的中斷，PAH 患者的診斷和治療開始出現延誤。此外，新型多環芳烴治療方法的研究和開發受到阻礙，影響了潛在治療方法的研發。醫療資源的重新配置和經濟的不確定性進一步加劇了PAH市場的壓力。疫情對市場動態和多環芳烴管理的長期影響仍然令人擔憂，解決這些問題需要繼續努力。

磷酸二酯酶 5 (PDE-5) 抑制劑預計在預測期內將成為最大的細分市場

磷酸二酯酶-5 (PDE-5) 抑制劑部分在預測期內佔據最大佔有率。他達拉非和Sildenafil等磷酸二酯酶 5 (PDE-5) 抑制劑對於肺動脈高血壓市場至關重要。這些藥物透過抑制 5 型磷酸二酯酶發揮作用，從而擴張肺動脈並改善血流。這些抑制劑透過特異性靶向 PDE-5 酶來放鬆肺血管平滑肌細胞並降低肺動脈壓力。 PDE-5抑制劑廣泛用於PAH的治療，且常採用聯合治療以增強療效。

預計學名藥在預測期內的複合年成長率最高。

隨著時間的推移，學名藥行業顯示出盈利成長，因為它涉及品牌 PAH 治療的非專利藥替代品。學名藥為患者提供了更實惠的選擇，因為它們是生物等效的替代品。該部分將使 PAH 治療更容易獲得，並允許更多患者購買和服用處方藥物。這些因素正在推動該領域的成長。

佔比最高的地區

北美肺動脈高血壓（PAH）市場預計將佔據最大佔有率。由於治療方法的進步、診斷方法的增強和認知的提高，PAH 診斷的頻率正在增加。此外，北美廣泛的醫療保健系統和高昂的醫療費用提供了最先進的治療方法和藥物。此外，北美多環芳烴研究、開發和普及的關鍵因素是製藥公司、研究機構和醫療保健提供者之間的合作。

複合年成長率最高的地區：

歐洲肺動脈高血壓市場在一段時間內持續成長。患者和醫療保健專業人員的治療方法改進和診斷意識的提高正在推動該地區的市場成長。歐洲也擁有完善的醫療保健基礎設施，有助於獲得這些先進的治療方法。此外，該地區製藥公司、研究機構和醫療機構之間的合作正在推動新藥和治療方法的推出，進一步推動該地區的成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肺動脈高血壓市場：依產品

  • 內皮素受體拮抗
  • 可溶性鳥苷酸環化酶 (sGC) 刺激劑
  • 磷酸二酯酶 5 (PDE-5) 抑制劑
  • 細胞週期蛋白類似物
  • 其他產品

第6章全球肺動脈高血壓市場：依類型

  • 創新的
  • 非專利的
  • 品牌
  • 其他類型

第7章全球肺動脈高血壓市場：依給藥途徑

  • 口服
  • 靜脈
  • 其他給藥途徑

第8章全球肺動脈高血壓市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 網路藥房
  • 其他最終用戶

第9章全球肺動脈高血壓市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Actelion Pharmaceuticals ltd.
  • Bayer
  • Eli lilly and company
  • Gilead Sciences, Inc.
  • Gsk Plc
  • Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • Johnson & Johnson
  • Lupin
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd.
  • Taizhou Tianrui Chemical Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc
Product Code: SMRC24719

According to Stratistics MRC, the Global Pulmonary Arterial Hypertension Market is accounted for $5.4 billion in 2023 and is expected to reach $8.9 billion by 2030 growing at a CAGR of 7.4% during the forecast period. High blood pressure in the arteries supplying blood to the lungs is a defining feature of pulmonary arterial hypertension, a rare and dangerous condition. Breathing difficulties and heart failure are some of the complications that can result from this elevated pressure in the pulmonary arteries. This market includes a variety of treatments intended to control and alleviate PAH symptoms, with the ultimate goal of enhancing patients' general health and outlook.

According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

PAH is often associated with underlying conditions such as connective tissue diseases, congenital heart defects, and liver disease, among others. As the incidence of these risk factors rises globally, so does the prevalence of PAH. Additionally, lifestyle factors such as sedentary behavior and exposure to environmental toxins contribute to the escalation of PAH cases. The aging population further amplifies the risk, as PAH is more commonly diagnosed in older individuals. This growing burden of risk factors has led to an upsurge in the number of people affected by PAH, driving the demand for innovative treatments, pharmaceutical interventions, and medical advancements.

Restraint:

High costs associated with treatment options

The high cost of available treatment options is a major barrier to the pulmonary arterial hypertension market. The cost of PAH drugs, which include phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, can be prohibitive for patients and healthcare systems alike. Optimizing disease management is made more difficult by the complex nature of PAH diagnosis and treatment, which calls for specialized healthcare infrastructure and knowledge. These financial and practical limitations make it difficult to provide effective PAH care and emphasize the need for more readily available and reasonably priced therapeutic options.

Opportunity:

Development of innovative therapeutic approaches

The market for pulmonary arterial hypertension offers a number of opportunities, including the creation of novel treatment strategies and focused medications. Technological and scientific developments have made it possible to find new treatment approaches that are more effective in addressing the underlying causes of PAH. A larger patient pool may result from improved early diagnosis and raised awareness.

Threat:

Limited treatment options

The market for pulmonary arterial hypertension is seriously threatened by the scarcity of treatment options and the difficulty of creating efficient treatments. Because PAH is an uncommon and serious illness, developing new medications is difficult due to the disease's complex pathophysiology and the requirement for novel mechanisms of action. However, the lack of varied and focused treatment options could restrict patient options and impede the PAH market's overall expansion.

COVID-19 Impact:

The COVID-19 pandemic has influentially impacted the market. During lockdowns, patients with PAH had difficulty getting access to medical care and treatments. Patients with PAH experienced delays in diagnosis and treatment initiation due to disruptions in the healthcare system. Additionally, the pipeline of possible medications was impacted by hampered research and development efforts for novel PAH therapies. The PAH market was further strained by reallocations of healthcare resources and economic uncertainties. The pandemic's long-term effects on market dynamics and PAH management are still a worry, and solving these issues will take continued work.

The Phosphodiesterase-5 (PDE-5) Inhibitors segment is expected to be the largest during the forecast period

Phosphodiesterase-5 (PDE-5) Inhibitors segment commanded the largest share over the projected period. Phosphodiesterase-5 (PDE-5) Inhibitors like tadalafil and sildenafil are essential to the market for pulmonary arterial hypertension. These medications function by blocking the phosphodiesterase type 5 enzyme, which causes the pulmonary arteries to dilate and improve blood flow. These inhibitors lower pulmonary arterial pressure by relaxing smooth muscle cells in the pulmonary vessels by specifically targeting the PDE-5 enzyme. PDE-5 inhibitors are frequently used in combination therapy to improve treatment efficacy because they are widely used in the management of PAHs.

The generics segment is expected to have the highest CAGR during the forecast period

The generics segment is showing profitable growth over the period of time as it deals with the accessibility of generic substitutes for name-brand PAH drugs. Generic medications offer patients more affordable options since they are bioequivalent substitutes for their name-brand counterparts. This section helps make PAH therapies more accessible, which makes it possible for a larger group of patients to afford and take their prescribed drugs. These elements are boosting segments growth.

Region with largest share:

The pulmonary arterial hypertension (PAH) market in North America is expected to hold largest share. The frequency of PAH diagnoses is on the rise, which can be attributed to advances in treatment options, enhanced diagnostic methods, and increased awareness. Furthermore, more access to cutting-edge treatments and pharmaceuticals is made possible by North America's extensive healthcare system and high healthcare spending. Moreover, a major factor in the advancement of PAH research, development, and uptake in the North American region has been the cooperative efforts of pharmaceutical companies, research institutes, and healthcare providers.

Region with highest CAGR:

The European market for pulmonary arterial hypertension has grown consistently over a period of time. Improvements in treatment options, growing awareness among patients and healthcare professionals in diagnosis have all fueled market growth in the region. Europe also boasts a well-established healthcare infrastructure, facilitating the accessibility of these advanced treatments. Additionally, the collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations in the region have resulted in the introduction of novel drugs and therapies, further propelling regional growth.

Key players in the market:

Some of the key players in Pulmonary Arterial Hypertension market include Actelion pharmaceuticals ltd., Bayer, Eli lilly and company, Gilead sciences, inc., Gsk plc , Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Johnson & johnson , Lupin, Pfizer inc, Sun pharmaceutical industries ltd., Taizhou Tianrui Chemical Co., Ltd, Teva pharmaceutical industries ltd., United therapeutics corporation and Viatris inc.

Key Developments:

In December 2023, G+Flas Life Sciences and Bayer AG have signed a letter of intent (LOI) to collaborate on the development of novel Crispr genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. This LOI underscores the shared interest of G+FLAS and Bayer AG in developing tomato seeds that not only meet high commercial standards but also incorporate cutting-edge genetic traits through G+Flas's Crispr genome editing technology.

In October 2023, Viatris Inc., a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business. With this announcement the Company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the Company's previously communicated range, after considering the estimated retained value.

Products Covered:

  • Endothelin Receptor Antagonists
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Prostacyclin Analogs
  • Other Products

Types Covered:

  • Innovative
  • Generics
  • Branded
  • Other Types

Route of Administrations Covered:

  • Oral
  • Intravenous/ subcutaneous
  • Other Routes of Administrations

End Users Covered:

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pulmonary Arterial Hypertension Market, By Product

  • 5.1 Introduction
  • 5.2 Endothelin Receptor Antagonists
  • 5.3 Soluble Guanylate Cyclase (sGC) Stimulators
  • 5.4 Phosphodiesterase-5 (PDE-5) Inhibitors
  • 5.5 Prostacyclin Analogs
  • 5.6 Other Products

6 Global Pulmonary Arterial Hypertension Market, By Type

  • 6.1 Introduction
  • 6.2 Innovative
  • 6.3 Generics
  • 6.4 Branded
  • 6.5 Other Types

7 Global Pulmonary Arterial Hypertension Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Other Routes of Administrations

8 Global Pulmonary Arterial Hypertension Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other End Users

9 Global Pulmonary Arterial Hypertension Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Actelion Pharmaceuticals ltd.
  • 11.2 Bayer
  • 11.3 Eli lilly and company
  • 11.4 Gilead Sciences, Inc.
  • 11.5 Gsk Plc
  • 11.6 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
  • 11.6 Johnson & Johnson
  • 11.8 Lupin
  • 11.9 Pfizer Inc
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Taizhou Tianrui Chemical Co., Ltd
  • 11.12 Teva Pharmaceutical Industries Ltd.
  • 11.13 United Therapeutics Corporation
  • 11.14 Viatris Inc

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 4 Global Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 5 Global Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 6 Global Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 7 Global Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 10 Global Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 11 Global Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 12 Global Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 13 Global Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 15 Global Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 16 Global Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 17 Global Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 19 Global Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 21 Global Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 24 North America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 25 North America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 26 North America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 27 North America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 28 North America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 29 North America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 30 North America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 31 North America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 32 North America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 33 North America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 North America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 35 North America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 36 North America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 37 North America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 38 North America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 North America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 41 North America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Europe Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 48 Europe Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 49 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Europe Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 Europe Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 52 Europe Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 53 Europe Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 54 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 Europe Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 56 Europe Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 57 Europe Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 58 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 59 Europe Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 60 Europe Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 61 Europe Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 62 Europe Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 63 Europe Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 66 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 67 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 68 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 69 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 70 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 73 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 74 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 75 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 76 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 77 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 78 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 79 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 80 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 83 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 84 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 88 South America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 89 South America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 90 South America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 91 South America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 South America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 93 South America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 94 South America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 95 South America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 96 South America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 97 South America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 98 South America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 99 South America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 100 South America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 101 South America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 102 South America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 103 South America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 104 South America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 105 South America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
  • Table 108 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
  • Table 109 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
  • Table 110 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
  • Table 111 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
  • Table 112 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 113 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
  • Table 114 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
  • Table 115 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
  • Table 116 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
  • Table 117 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 118 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 119 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
  • Table 120 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 121 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
  • Table 122 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 124 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 125 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 126 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)